Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice

Journal of Nutrition

Volumn 130, Issue 9, 2000, Pages 2361-2366

  Lenhard, J M ^a   Croom, D K ^a   Weiel, J E ^a   Spaltenstein, A ^a   Reynolds, D J ^a   Furfine, E S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Dyslipidemia; Fat; HIV; Lipodystrophy; Protease inhibitors

Indexed keywords

ALKALINE PHOSPHATASE; AMPRENAVIR; BILIRUBIN; FATTY ACID; GLUCOSE; GLYCEROL; INDINAVIR; INSULIN; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ADIPOSE TISSUE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FAT INTAKE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEROL BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPODYSTROPHY; MALE; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 0033866125     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/130.9.2361     Document Type: Article

References (29)

1. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
2. Vascular complications associated with use of HIV protease inhibitors
3. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
4. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
5. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans
6. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
7. The HIV-1 protease as a therapeutic target for AIDS
8. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
9. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
10. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction
11. Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir
12. 'Buffalo hump' in men with HIV-1 infection
13. Lipodystrophy in patients naive to HIV protease inhibitors
14. Lipodystrophia with protease inhibitors in HIV patients
15. Visceral abdominal-fat accumulation associated with use of indinavir
16. Changing patterns of mortality across Europe in patients infected with HIV
17. Crixivan capsules (indinavir sulfate)
18. Nelfinavir mesylate: A protease inhibitor
19. Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: Lessons learned from the Pima Indians
20. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
21. Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting
22. Marked hyperlipidemia on ritonavir therapy
23. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice
24. Indinavir-associated lipodystrophy
25. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
26. Influence of diet and genetics on metabolic abnormalities in mice treated with HIV protease inhibitors
27. Dietary obesity in nine inbred mouse strains
28. Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans